Catheter Thrombectomy in Patients With Massive Pulmonary Embolism
Launched by STRAUB MEDICAL AG · Apr 11, 2006
Trial Information
Current as of May 09, 2025
Terminated
Keywords
ClinConnect Summary
Official Title: Compassionate Use of Catheter Thrombectomy (Aspirex 11F) in Patients With Massive Pulmonary Embolism
Principal Investigator: Nils Kucher, MD, Cardiovascular Division, Interventional Cardiology, Andreas Grüntzig Catheterization Laboratories, Raemistrasse 100 University Hospital Zurich, 8091 Zurich, Switzerland, Phone: +41 1 255 8762, kuchernils@yahoo.com
Sponsor: Straub Medical AG, Straubstrasse, 73 23 Wangs, Schweiz
August 29, 2005
I. BACKGROUND AND SIGNIFICANCE
A) Historical Background
Acute pulmonary embolism (PE) is a potentially life-threatening disease with an ove...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients \>= 18 years of age with pulmonary embolism and cardiogenic shock, defined as a systolic arterial pressure \<= 90 mmHg, a drop in systolic arterial pressure \>= 40 mmHg for \>= 15 minutes, or ongoing administration of catecholamines for systemic arterial hypotension
- • 2. Subtotal or total filling defect in the left and/or right main pulmonary artery due to massive PE, as assessed by chest computed tomography or by conventional pulmonary angiography
- • 3. Right ventricular dysfunction on echocardiography: RV systolic hypokinesis and/or RV dilation (optional)
- 4. Failed thrombolysis or at least one of the following contraindications to PE thrombolysis present:
- • Active bleeding
- • History of intracranial bleeding
- • Surgery, delivery, organ biopsy, puncture of a non-compressible vessel within 10 days
- • History of stroke
- • Gastrointestinal bleeding within 10 days
- • Significant trauma within 15 days
- • Head injury requiring hospitalization within 1 year
- • Active cancer with known hemorrhagic risk
- • Neurosurgery or ophthalmologic surgery within the past year
- • Platelets \< 50,000 or INR \>2.0
- • Pregnancy
- • Exclusion Criteria
- • 1. Systemic (paradoxical) embolism in the presence of an atrial septal defect or patent foramen ovale
- • 2. Free floating right heart thrombi, left heart thrombi
- • 3. Life expectancy due to underlying disease less than one month
About Straub Medical Ag
Straub Medical AG is a pioneering medical device company dedicated to advancing cardiovascular health through innovative solutions. With a focus on the development and commercialization of cutting-edge technologies for the treatment of vascular diseases, Straub Medical AG combines rigorous research and clinical expertise to enhance patient outcomes. Committed to quality and safety, the company collaborates with healthcare professionals and institutions worldwide to deliver effective, minimally invasive treatment options. Its extensive portfolio reflects a strong commitment to improving healthcare standards and addressing unmet medical needs in the cardiovascular field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Luzern, , Switzerland
Bad Neustadt, , Germany
Kiel, , Germany
Leipzig, , Germany
Magdeburg, , Germany
Patients applied
Trial Officials
Nils Kucher, MD
Principal Investigator
Universitätsspital Zürich (USZ) Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials